



# Structural revision of halipeptins: synthesis of the thiazoline unit and isolation of halipeptin C

Carmela Della Monica,<sup>c</sup> Antonio Randazzo,<sup>b</sup> Giuseppe Bifulco,<sup>a</sup> Paola Cimino,<sup>a</sup> Maurizio Aquino,<sup>c</sup> Irene Izzo,<sup>c</sup> Francesco De Riccardis<sup>c,\*</sup> and Luigi Gomez-Paloma<sup>a,\*</sup>

<sup>a</sup>Dipartimento di Scienze Farmaceutiche, Università di Salerno, via Ponte Don Melillo, 84084 Fisciano (SA), Italy

<sup>b</sup>Dipartimento di Chimica delle Sostanze Naturali, Università di Napoli Federico II, via D. Montesano 49, 80131 Napoli, Italy


<sup>c</sup>Dipartimento di Chimica, Università di Salerno, Via S. Allende, 84081 Baronissi (SA), Italy

Received 30 May 2002; revised 20 June 2002; accepted 25 June 2002

**Abstract**—The structural revision of the anti-inflammatory marine metabolites halipeptin A (**1**) and B (**2**) along with the isolation of the new related product halipeptin C (**3**) are reported. In particular, the heterocyclic portion of the molecule, incorrectly assigned as an oxazetidione ring, has now been characterised as a thiazoline unit by comparison of the spectral data of the natural products (**1–3**) with an appropriate synthetic model (**10**). GIAO calculated <sup>13</sup>C NMR chemical shifts for oxazetidione and thiazoline model compounds provide additional support to the revised structure. © 2002 Elsevier Science Ltd. All rights reserved.

Halipeptins A (**1**) and B (**2**) are cyclic depsipeptides displaying a potent in vivo anti-inflammatory activity (60% of carrageenan induced edema reduction at a intraperitoneal dose of 0.3 mg/Kg in mice).<sup>1</sup> Their structures feature the presence of common coded amino acid residues (2×L-Ala) along with unusual units, such as the polysubstituted decanoic acid HTMMD, N-methyl-δ-hydroxyisoleucine (NMe-δOH-Ile) and the heterocyclic version of an α,α-disubstituted amino acid which was incorrectly identified as a methyloxazetidione–carboxylic acid residue (OMCA) mainly on the basis of NMR and HRFABMS data.

The opportunity of re-examine the spectral data of halipeptins came with the isolation, from the same Vanuatu species of *Haliclona*, of a new minor related compound, named halipeptin C (**3**). Although all the NMR data (see Table 1 and HMBC correlations of **3**) could be readily interpreted assuming that halipeptin C was a derivative of **2** bearing a L-NMeVal in place of the NMe-δOH-Ile residue, HRESIMS data suggested that its molecular formula contained an unexpected sulphur atom. Indeed, the pseudomolecular ion peak of **3** at *m/z* 605.3360 (M+Na<sup>+</sup>, 605.33487 calculated for C<sub>29</sub>H<sub>50</sub>N<sub>4</sub>NaO<sub>6</sub>S versus 605.35263 calculated for C<sub>29</sub>H<sub>50</sub>N<sub>4</sub>NaO<sub>8</sub>) clearly favoured the molecular formula containing a sulphur in place of two oxygen atoms.



\* Corresponding authors. Tel.: +39-089-962811; fax: +39-089-962828 (L.G.P.); Tel.: +39-089-965230; fax: +39-089-965296; e-mail: dericca@unisa.it; gomez@unisa.it

**Table 1.**  $^1\text{H}$ ,  $^{13}\text{C}$  and  $^{15}\text{N}$  NMR data of of halipeptin C (3) ( $\text{CDCl}_3$ , 500 MHz)

Residue	$\delta_{\text{H}}^{\text{a}}$ , mult., $J$ in Hz	$\delta_{\text{C}}^{\text{a}}$	$^1\text{H}$ - $^{13}\text{C}$ HMBC
<b>Ala1</b>			
CO		169.6	
$\alpha$	4.71, quintet, 7.6	49.9	CO
$\beta$	1.41, d, 7.6	18.2	C $\alpha$ , CO
N	7.01, d, 7.6		CO-NMeVal
<b>NMeVal</b>			
CO		169.9	
$\alpha$	4.98	64.8	
$\beta$	2.56, m	26.4	
Me-1	0.93, d, 6.3	17.7	C $\alpha$ , C $\beta$ , Me-2
Me-2	0.98, d, 6.3	21.0	C $\alpha$ , C $\beta$ , Me-1
NMe	2.81, s	30.5	C $\alpha$ , CO- $\alpha$ -MeCys
<b><math>\alpha</math>-MeCys</b>			
CO		171.9	
$\alpha$		83.6	
Me- $\alpha$	1.49, s	23.0	C $\alpha$ , C $\beta$ , CO
$\beta_1$	3.31, d, 12.0	43.6	
$\beta_2$	4.15, d, 12.0		
N			
<b>Ala2</b>			
CN(S)		177.3	
$\alpha$	4.82, quintet, 7.4	48.8	CO-HTMHD
$\beta$	1.50, d, 7.4	22.1	C $\alpha$ , CO
N	7.23, d, 7.4		CO-HTMHD
<b>HTMHD</b>			
1		173.6	
2		45.6	
Me'-2	1.12, s	25.9	Me''-2, C-1, C-2, C-3
Me''-2	1.20, s	21.9	Me'-2, C-1, C-2, C-3
3	4.71, d, 2.3	82.3	CO-Ala1
4	1.93, m	34.0	
Me-4	0.80, d, 6.5	14.1	C-3
5	1.30, m	32.0	
6	1.34, m		
7	1.45, m	34.1	
8	1.50, m		
9	3.55, quintet, 5.3	72.0	
10	1.30, m	39.8	
9	1.43, m		
10	1.33	17.5	
10	0.91, t, 6.0	14.9	C-8, C-9

<sup>a</sup> Chemical shift values are referred to  $\text{CHCl}_3$  ( $\delta_{\text{H}}=7.26$ ) and  $^{13}\text{CHCl}_3$  ( $\delta_{\text{C}}=77.0$ ) as internal standards.

Careful HRESIMS measurements revealed that this was also the case for the parent compound halipeptin A, for which a pseudomolecular ion peak could be found at  $m/z$  649.3628 ( $\text{M}+\text{Na}^+$ , 649.3611 calculated for  $\text{C}_{31}\text{H}_{54}\text{N}_4\text{NaO}_6\text{S}$  versus 649.3788 calculated for  $\text{C}_{31}\text{H}_{54}\text{N}_4\text{NaO}_8$ ).<sup>†</sup> The new molecular formulas of the

<sup>†</sup> Actually, our first HRMS measurements on **1** gave pseudomolecular ion peaks that were more in agreement with the molecular formula  $\text{C}_{31}\text{H}_{54}\text{N}_4\text{O}_9$  than with  $\text{C}_{31}\text{H}_{54}\text{N}_4\text{O}_7\text{S}$ , leading to a misinterpretation of its NMR data. However, new HRMS data on **1** and **3** were obtained on a superior instrumentation (API QSTAR Pulsar) capable of reaching a resolution of about 20000 in that particular mass range.



halipeptin family indicated that the original assignment of the heterocycle portion as OMCA was incorrect.

A literature search led to the conclusion that  $^1\text{H}$  and  $^{13}\text{C}$  NMR data of **1**, **2** and **3** were consistent with the presence of a methylthiazoline unit.<sup>2</sup>

In order to gather conclusive evidences for the structural revision of these molecules (see Table 2 for spectral data) we synthesised a model thiazoline unit (Schemes 1 and 2). The synthesis of  $\Delta^2$ -thiazoline fragment was based on a four steps preparation of (*R*)-2-methylcysteine hydrochloride (**4**), reported by Pattenden and co-workers in 1993.<sup>3</sup> Esterification of **4** with  $\text{HCl}/\text{MeOH}$ <sup>4</sup> furnished a mixture the desired methyl ester **6** and the corresponding dimeric amino acid **5** in variable ratio (Scheme 1). Reduction<sup>5</sup> of the disulphide bond with  $\text{PPh}_3$  gave the expected (*R*)-2-methylcysteine hydrochloride methyl ester (**6**) in 80% overall yield from **4**.

Coupling<sup>3</sup> of **6** with the 2-(*S*)-*t*-butoxycarbonylaminopropionitrile (**9**), easily prepared in 74% yield from commercially available (*L*)-alaninamide hydrochloride (**7**) through *N*-Boc protection<sup>6</sup> and efficient dihydration of the amide moiety<sup>7</sup> (Scheme 2), yielded the desired 2-[1-(*S*)-*tert*-butoxycarbonylaminoethyl]-4-(*R*)-methyl-4,5-dihydrothiazole-4-carboxylic acid methyl ester **10**.<sup>‡</sup>


Final support to the revised structure came from the comparison of GIAO (gauge including atomic orbitals) calculated<sup>8</sup>  $^{13}\text{C}$  and  $^{15}\text{N}$  NMR chemical shift of four model compounds, representing the two diastereomeric couples of oxazetidine (**11a** and **11b**) and thiazoline (**12a** and **12b**) units, respectively, with those of the natural product **1** (see Table 2), following an approach recently reported by our group.<sup>9</sup>



<sup>‡</sup> Physical data for compound **10**:  $[\alpha]_{\text{D}}^{20}=-23$  ( $c$  1.0,  $\text{CHCl}_3$ );  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.40 (1 H, d,  $J=7.3$  Hz,  $\text{CHCH}_3$ ), 1.42 (9 H, s,  $(\text{CH}_3)_3$ ), 1.50 (3 H, s,  $\text{CH}_3$ ), 3.14 (1 H, d,  $J=11.3$  Hz,  $\text{CHH}$ ), 3.75 (1 H, d,  $J=11.3$  Hz,  $\text{CHH}$ ), 3.76 (3 H, s,  $\text{OCH}_3$ ), 4.50 (1 H, m,  $\text{CHCH}_3$ ), 5.23 (1 H, m,  $\text{NH}$ );  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  20.43 ( $\text{CHCH}_3$ ), 23.80 ( $\text{CH}_3$ ), 28.30 ( $\times 3$ ,  $(\text{CH}_3)_3$ ), 41.63 ( $\text{CH}_2\text{S}$ ), 49.18 ( $\text{CH}$ ), 52.81 ( $\text{OCH}_3$ ), 79.76 ( $\text{OC}(\text{CH}_3)_3$ ), 84.20 ( $\text{C}(\text{CH}_3)\text{CO}_2\text{Me}$ ), 154.86 ( $\text{NCO}_2$ ), 173.53 and 174.55 ( $\text{SC}=\text{N}$  and  $\text{CO}_2\text{Me}$ ); HRESIMS:  $m/z$  303.1372 (303.1379 calculated for  $\text{C}_{13}\text{H}_{23}\text{N}_2\text{O}_4\text{S}$ ).


**Table 2.** Calculated and experimental  $^{13}\text{C}$  chemical shifts values (ppm) of natural and synthetic compounds

Residue	Calculated $^{13}\text{C}$ chemical shifts values	Residue	Calculated $^{13}\text{C}$ chemical shifts values	Experimental $^{13}\text{C}$ chemical shifts values	
				Natural compound <b>1</b>	Synthetic compound <b>10</b>
Oxazetidione unit		Thiazoline unit			
<b>11a/11b</b>		<b>12a/12b</b>			
<b>Ala2</b>		<b>Ala2</b>			
CO	182.2/180.4	SC=N	178.2/178.1	177.3	173.5
$\alpha$	44.2/47.8	$\alpha$	48.0/47.8	48.5	49.2
$\beta$	18.1/18.8	$\beta$	22.1/21.5	22.0	20.4
N	-247.1/-247.4	N	-109.4/-107.2	-89.3	-
<b>OMCA</b>		$\alpha$ -MeCys			
CO	168.4/170.6	CO	174.2/173.6	172.4	174.6
$\alpha$	77.8/76.1	$\alpha$	78.0/79.1	83.3	84.2
$\beta$	57.0/55.0	$\beta$	40.9/43.1	44.2	41.6
Me- $\alpha$	23.0/22.0	Me- $\alpha$	29.5/27.7	23.1	23.8

**Scheme 1.** Reagents and conditions: (a) 5.0 equiv. of  $\text{SOCl}_2$ , MeOH, reflux, 12 h, 80%; (b) 4.5 equiv. of  $\text{PPh}_3$ , DME/MeOH/ $\text{H}_2\text{O}$ , 7:2:1, 90°C, 12 h, 100%.

Notably, this set of data would *slightly* favour the *R* absolute configuration at C-4 of the thiazoline unit, a finding which is not surprising, considering that this configuration is expected from the cyclisation of a *L*- $\alpha$ -methylcystein amino acid residue and taking into account that all the amino acid residues of halipeptins appear to belong to the *L* series.

Extraction and isolation of **3** followed the same protocol used for **1** and **2**.<sup>1,8</sup> Structure elucidation of **3** was

**Scheme 2.** Reagents and conditions: (a) 1.5 equiv. of  $\text{Boc}_2\text{O}$ , 1.5 equiv. of  $\text{Et}_3\text{N}$ , MeOH, 12 h, 90%; (b) 2.2 equiv. of  $(\text{CF}_3\text{CO})_2\text{O}$ , 4.4 equiv. of pyridine, THF, 0°C  $\rightarrow$  rt, 3 h, 82%; (c) 1.0 equiv. of **6**, 1.0 equiv. of **9**, 1.0 equiv. of  $\text{Et}_3\text{N}$ , MeOH, 65°C, 12 h, 30%.

<sup>8</sup> Halipeptin C (**3**), white amorphous solid,  $[\alpha]_{\text{D}} = -30$  ( $c$  0.3,  $\text{CHCl}_3$ ), was purified on a  $\mu$ -Bondapak C-18 column (7.8 $\times$ 300 mm) with linear gradient elution,  $\text{H}_2\text{O}/\text{CH}_3\text{OH}$ , 75:25–0:100 in 30 min ( $t_{\text{R}} = 20.5$  min). HRESIMS:  $m/z$  605.3360 ( $\text{M}+\text{Na}^+$ , 605.33487 calculated for  $\text{C}_{29}\text{H}_{50}\text{N}_4\text{NaO}_6\text{S}$ ). For NMR data, see Table 1.

straightforward due to the very limited differences existing between **2** and **3** (their  $^1\text{H}$  NMR spectra were virtually superimposable, except for few signals). However, besides the opportunity to correct the assignment of the OMCA unit, the structural study of **3** was useful also for stereochemical reasons. In fact, HPLC Marfey analysis<sup>10</sup> of the acidic hydrolysate of **3** allowed us to assign the *N*-MeVal residue to the *L* series, with the important implication that the same absolute configuration is very likely present in the *N*Me- $\delta$ OH-Ile of **1** and **2**.

## Acknowledgements

We thank Professor Shigeki Matsunaga (University of Tokyo, Japan) for helpful discussions on the structural revision of halipeptin A. Financial support was provided by the Università di Salerno, Consiglio Nazionale delle Ricerche (CNR, Roma) and Ministero dell'Istruzione, dell'Università e della Ricerca Scientifica e Tecnologica (MIUR, Roma) through the PRIN 1999–2001 and 2001–2003 programs.

## References

- Randazzo, A.; Bifulco, G.; Giannini, C.; Bucci, M.; Debitus, C.; Cirino, G.; Gomez-Paloma, L. *J. Am. Chem. Soc.* **2001**, *123*, 10870–10876.
- Carmeli, S.; Paik, S.; Moore, R. E.; Patterson, G. M. L.; Yoshida, W. Y. *Tetrahedron Lett.* **1993**, *34*, 6681–6684.
- Mulqueen, G. C.; Pattenden, G.; Whiting, D. A. *Tetrahedron* **1993**, *49*, 5359–5364.

4. Ronald, G. W.; Malcolm, W. H.; Stammer, C. H. *J. Org. Chem.* **1969**, *34*, 576–580.
5. Corey, E. J.; Mehrotra, M. M. *Tetrahedron Lett.* **1988**, *29*, 57–60.
6. Yuste, F.; Ortiz, B.; Carrasco, A.; Peralta, M.; Quintero, L.; Sanchez-Obregon, R.; Walls, F.; Garcia Ruano, J. L. *Tetrahedron: Asymmetry* **2000**, *11*, 3079–3090.
7. Kruijtzter, J. A. W.; Lefeber, D. J.; Liskamp, R. M. J. *Tetrahedron Lett.* **1997**, *38*, 5335–5338.
8. Ditchfield, R. *Mol. Phys.* **1974**, *27*, 789–807.
9. Barone, G.; Gomez-Paloma, L.; Duca, D.; Silvestri, A.; Riccio, R.; Bifulco, G. *Chem. Eur. J.* **2000**, *8*, 3233–3239.
10. Marfey, P. *Carlsberg Res. Commun.* **1984**, *49*, 591–596.